Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

44.87 +0.44 (+0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals

< Previous 1 2 3 4 Next >
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its  
Via Benzinga
Why Shares of Schrödinger Rose This Week
Interest in the company's AI platform continues to drive the stock. 
Via The Motley Fool
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
Agios Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Looking Into Agios Pharmaceuticals Return On Capital Employed
  
Via Benzinga
Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
Via Benzinga
7 Analysts Have This to Say About Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Agios Pharmaceuticals: Q1 Earnings Insights
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split. 
Via Benzinga
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
  Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) jumped 48.5% to $19.90 after Novo Nordisk announced it will acquire the company for $20 per share in cash. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Agios Pharmaceuticals: Q2 Earnings Insights
  Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
U.S. Stock Futures Higher; All Eyes On Inflation Data
Pre-open movers 
Via Benzinga
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
With the US stock futures trading slightly higher this morning on Wednesday after recording losses in the previous session, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.